These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 133833)

  • 1. Steroid atrophy--a histological appraisal.
    Jones EW
    Dermatologica; 1976; 152 Suppl 1():107-15. PubMed ID: 133833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methods for the assessment of skin atrophogenicity of topical corticosteroids.
    Marks R
    Dermatologica; 1976; 152 Suppl 1():117-26. PubMed ID: 133834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical betamethasone 17-valerate is an anticorticosteroid in the rat. 1. Dermal atrophy.
    Young JM; Yoxall BE; Wagner BM
    Br J Dermatol; 1978 Dec; 99(6):655-63. PubMed ID: 737128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of acid mucopolysaccharide synthesis by hydrocortisone, hydrocortisone 17-butyrate and betamethasone 17-valerate.
    Saarni H; Hopsu-Havu VK
    Br J Dermatol; 1977 Nov; 97(5):505-7. PubMed ID: 145236
    [No Abstract]   [Full Text] [Related]  

  • 5. Corticosteroid effect on epidermal cell size.
    Delforno C; Holt PJ; Marks R
    Br J Dermatol; 1978 Jun; 98(6):619-23. PubMed ID: 678451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial comparing hydrocortisone 17-butyrate to betamethasone 17-valerate in a series of patients with eczematous skin diseases.
    Thormann J; Brodthagen H
    Dermatologica; 1976; 152 Suppl 1():209-14. PubMed ID: 782955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial.
    Cossmann M; Welzel J
    Br J Dermatol; 2006 Oct; 155(4):700-6. PubMed ID: 16965418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo.
    Serup J; Holm P
    Dermatologica; 1985; 170(4):189-94. PubMed ID: 3888708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid-induced atrophy in an animal and human model.
    Kirby JD; Munro DD
    Br J Dermatol; 1976 Mar; 94 suppl 12():111-9. PubMed ID: 1268071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound.
    Kerscher MJ; Korting HC
    Acta Derm Venereol; 1992; 72(3):214-6. PubMed ID: 1357864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids.
    Schäfer-Korting M; Korting HC; Kerscher MJ; Lenhard S
    Clin Pharmacol Ther; 1993 Oct; 54(4):448-56. PubMed ID: 8222488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream.
    Korting HC; Vieluf D; Kerscher M
    Eur J Clin Pharmacol; 1992; 42(2):159-61. PubMed ID: 1618247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development and regression of dermal corticosteroid atrophy. 1. Change in the skinfold thickness].
    Lubach D; Hinz E
    Derm Beruf Umwelt; 1986; 34(5):146-9. PubMed ID: 2947794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The stability and blanching efficacy of betamethasone-17-valerate in emulsifying ointment.
    Ryatt KS; Feather JW; Mehta A; Dawson JB; Cotterill JA; Swallow R
    Br J Dermatol; 1982 Jul; 107(1):71-6. PubMed ID: 7104209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onset of the vasoconstrictor effect of diflucortolone valerate, betamethasone valerate, and fluocinolone acetonide ointments applied for varying periods under occlusive dressings.
    Szadurski J; Renz F; Gasser D
    Dermatologica; 1976; 153(4):236-42. PubMed ID: 1017533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of skin thickness: a comparison of two in vivo techniques with a conventional histometric method.
    Dykes PJ; Marks R
    J Invest Dermatol; 1977 Sep; 69(3):275-8. PubMed ID: 894062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma cortisol levels in normal volunteers receiving either betamethasone valerate or desoximetasone by topical application.
    Bromley PA; Müller FO; Malan J; Torres J; Vanderbeke O
    S Afr Med J; 1978 Aug; 54(6):239-41. PubMed ID: 362568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between in vivo skin blanching and in vitro release rate for betamethasone valerate creams.
    Shah VP; Elkins J; Skelly JP
    J Pharm Sci; 1992 Jan; 81(1):104-6. PubMed ID: 1619561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of corticosteroids on the growth and metabolism of fibroblasts cultured from human skin.
    Priestley GC
    Br J Dermatol; 1978 Sep; 99(3):253-61. PubMed ID: 81679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of serial dilution of betamethasone-17-valerate on blanching potential and chemical stability.
    Ryatt KS; Cotterill JA; Mehta A
    J Clin Hosp Pharm; 1983 Jun; 8(2):143-5. PubMed ID: 6875011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.